



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	09/299139-Conf. #2882
				Filing Date	April 23, 1999
				First Named Inventor	Jeffrey L. BROWNING
				Art Unit	1643
				Examiner Name	C. H. Yaen
Sheet	1	of	1	Attorney Docket Number	BGN-A013RCE

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CY	B1	WO-92/00329-A1	01-09-1992	Biogen, Inc., et al.	
CY	B2	WO-94/13808-A2	06-23-1994	Biogen, Inc., et al.	
CY	B3	WO-97/03687-A1	02-06-1997	Biogen, Inc.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
CY	C1	http://reutershealth.com/wellconnected/doc63.html			
	C2	Browning, Jeffrey L., et al., "Signaling through the Lymphotoxin β Receptor Induces the Death of Some Adenocarcinoma Tumor Lines," <i>J. Exp. Med.</i> , Vol. 183:867-878 (1996)			
	C3	Browning, Jeffrey L., et al., "Characterization of Surface Lymphotoxin Forms," <i>The Journal of Immunology</i> , Vol. 154:33-46 (1995)			
	C4	Gyorf, Zs., et al., "Alteration of the TNF Sensitivity and Membrane Viscosity of Target Cells," <i>Eur. Cytokine Netw.</i> , Vol. 7(2):167 (1996)			
	C5	Mendlovic, Shlomo, et al., "Induction of a Systemic Lupus Erythematosus-like Disease in Mice by a Common Human Anti-DNA Idiotype," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 85:2260-2264 (1988)			
	C6	Rennert, P.D., et al., "Normal Development of Lymph Nodes is Disrupted by Soluble LT beta Receptor - Ig Fusion Protein," <i>Eur. Cytokine Netw.</i> , Vol. 7(2):167 (1996)			
	C7	Smolen, Josef S., "Therapy of systemic lupus erythematosus: a look into the future," <i>Arthritis Res.</i> , Vol. 4(suppl. 3):S25-S30 (2002)			
	C8	Trethewey, Pat, "Systemic Lupus Erythematosus," <i>Dimensions of Critical Care Nursing</i> , Vol. 23(3):111-115 (2004)			
CY	C9	International Search Report Docket No. PCT/US97/19436, dated May 28, 1998			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Chrys M</i>	Date Considered	3/2/06
--------------------	----------------	-----------------	--------